Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Rating) Director Marijn E. Dekkers sold 171,455 shares of Ginkgo Bioworks stock in a transaction on Thursday, November 3rd. The shares were sold at an average price of $2.56, for a total value of $438,924.80. Following the completion of the transaction, the director now owns 2,021,132 shares of the company’s stock, valued at approximately $5,174,097.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Ginkgo Bioworks Price Performance
DNA opened at $2.39 on Tuesday. The company has a fifty day moving average price of $2.83 and a two-hundred day moving average price of $2.89. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. The firm has a market capitalization of $4.27 billion, a PE ratio of -1.22 and a beta of 0.89. Ginkgo Bioworks Holdings, Inc. has a 52 week low of $2.09 and a 52 week high of $15.86.
Ginkgo Bioworks (NYSE:DNA – Get Rating) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.36). Ginkgo Bioworks had a negative net margin of 549.38% and a negative return on equity of 47.12%. The company had revenue of $144.62 million during the quarter, compared to the consensus estimate of $69.95 million. As a group, analysts anticipate that Ginkgo Bioworks Holdings, Inc. will post -0.79 earnings per share for the current year.
Institutional Trading of Ginkgo Bioworks
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on DNA shares. Morgan Stanley assumed coverage on shares of Ginkgo Bioworks in a research report on Tuesday, October 4th. They set an “equal weight” rating and a $5.00 price target on the stock. Raymond James increased their price target on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the company an “outperform” rating in a research note on Tuesday, August 16th. Finally, BTIG Research boosted their price objective on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $7.41.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.
- Get a free copy of the StockNews.com research report on Ginkgo Bioworks (DNA)
- 3 Reasons Another Shoe May Drop for Skechers
- Is Clothier V.F. Corporation’s 7% Dividend Worth Trying On?
- Bulls Vs Bears: Mullen Automotive Short Interest Grows
- Palantir Falls Into The Hands Of Value Investors
- The Analysts Can’t Keep Up with Arista Networks Stock
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.